The clinical features of CKD-MBD are primarily due to the compromised renal excretion of minerals, leading to abnormality in circulating calcium, phosphorous, parathyroid hormone (PTH), and vitamin D. The secondary effects of this renal insufficiency include abnormalities in bone turnover, mineralization, volume, linear growth, strength, and ectopic calcification (vascular and soft tissues)3.
Opposite results were obtained by Shinoda et al. [ 14] who showed no abnormalities in bone turnover in mice with adiponectin-deficiency and adiponectin over expression in the liver.
CKD MBD is a systemic disease that links disorders of mineral and bone metabolism due to CKD to either one or all of the following: abnormalities of calcium, phosphorus, parathyroid hormone or vitamin D metabolism; abnormalities in bone turnover, mineralization, volume, linear growth or strength; or vascular or other soft-tissue calcification.
Abnormalities in lung ECM turnover and impaired structural organization significantly contribute to the development of BPD as shown by clinical and experimental studies.
Kidney Disease: Improving Global Outcomes defines chronic kidney disease-mineral and bone disorder (CKD-MBD) as a systemic syndrome characterized by abnormalities in serum calcium, phosphorus and parathyroid hormone (PTH) concentration, vitamin D metabolism, and bone turnover [ 1].
We hypothesized that the observed specific abnormalities in mitochondrial function seen in gba1−/− fish may be due to impaired mitochondrial biogenesis or mitochondrial protein turnover, possibly linked to impaired mitophagy.
These include vitamin D deficiency, 20– 26 abnormalities in serum levels of parathyroid hormone (PTH), 27– 34 calcium and phosphorus homeostasis, 35– 40 and in bone-turnover markers.
Figure 2: Lysosomal abnormalities in AGU fibroblasts.
Subgenual prefrontal cortex abnormalities in mood disorders.
There is therefore substantial concern about abnormalities in cloned humans.
